NITISINONE TABLETS

CYCLE Pharmaceuticals have invested 4 years to develop the NITISINONE TABLET that may be more convenient to patients and their caregivers

WHAT ARE CYCLE NITISINONE TABLETS?

NITISINONE TABLETS are tasteless and uncoated small tablets. For patients preferring tablets, NITISINONE TABLETS are only 7 mm in diameter and 2 mm high.

WHICH STRENGTHS ARE AVAILABLE?

NITISINONE TABLETS are available 2 mg, 5 mg and 10 mg strenghts (60 tablets bottle).

HOW ARE CYCLE NITISINONE TABLETS STORED?

NITISINONE TABLETS allow for room temperature storage (15 – 30°C). Allowing patients to travel freely without the need for access to refrigeration.

HOW NITISINONE TABLETS SHOULD BE ADMINISTERED?

NITISINONE TABLETS may be taken with or without food.

For infants, as the tablets are uncoated, these can be disintegrated in water using an oral syringe with a cap. Do not administer the suspension using a baby bottle.

For patients that can swallow semi-solid food, the tablets may be crushed and mixed with applesauce for administration.

The full administration instructions are available from the Patient Medication Information document.

HOW DO I ORDER CYCLE NITISINONE TABLETS?

Please call 1-855-831-5413 (toll-free from Canada) and choose OPTION 3.

NITISINONE TABLETS INDICATIONS

NITISINONE TABLETS, also known as NTBC tablets, are indicated for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Treatment with NITISINONE TABLETS should be initiated and supervised by a physician experienced in the treatment of HT-1.

IMPORTANT SAFETY INFORMATION ABOUT NITISINONE TABLETS

Contraindications:

  • Do not prescribe NITISINONE TABLETS to a patient that is hypersensitive to nitisinone or to any ingredient in the formulation.
  • Do not prescribe NITISINONE TABLETS if the patient is breast-feeding. Patients should not breast feed while taking NITISINONE TABLETS.

Warning and Precautions:

Endocrine and Metabolism: Elevated plasma tyrosine levels. Hematologic: Leukopenia and thrombocytopenia. Hepatic/Biliary/Pancreatic: Liver status should be assessed regularly through liver function tests. Neurologic: Variable degrees of intellectual disability and developmental delay have been observed in HT-1 patients treated with nitisinone. In patients treated with nitisinone who exhibit a change in neurologic status, a clinical laboratory assessment including plasma tyrosine should be performed. Ophthalmologic: Ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia have been reported in patients treated with nitisinone. Patients who develop photophobia, eye pain, or signs of inflammation such as redness, swelling, or burning of the eyes during treatment with NITISINONE TABLETS should undergo slit-lamp re-examination and immediate measurement of plasma tyrosine concentration.

Special Populations:

  • Pregnant women: NITISINONE TABLETS should be used in pregnancy only when the benefits of continued treatment are judged to outweigh the risks.
  • Nursing women: Because of the potential serious adverse reactions to nitisinone in nursing infants, mothers taking NITISINONE TABLETS should not breast-feed.
  • Pediatrics (< 18 years of age): Patients under 18 years should be monitored to ensure adequate control. It is recommended that a dietitian experienced in managing children with inborn errors of metabolism is consulted to design a low-protein diet restricted in tyrosine and phenylalanine.
  • Geriatrics (>65 years of age): Clinical studies of nitisinone did not include subjects over the age of 65 years, and no pharmacokinetic studies have been conducted in geriatric subjects.

Common Adverse Reactions:

The most common adverse reactions (≥1%) reported in patients treated with nitisinone (NTBC) are: Eye Disorders: conjunctivitis, corneal opacity, keratitis, photophobia, blepharitis and eye pain. Blood and lymphatic System Disorders: thrombocytopenia, leukopenia and granulocytopenia. Skin and subcutaneous tissue disorders: pruritis, exfoliative dermatitis and maculopapular rash. Investigations: elevated tyrosine levels.

PLEASE SEE PRODUCT MONOGRAPH
PLEASE SEE PATIENT MEDICATION INFORMATION LEAFLET
GO TO HOME PAGE